RANKL signaling pathway: a potential target for antiresorptive therapy in Rheumatoid Arthritis

Rheumatoid arthritis [RA] is a chronic polyarthritic autoimmunity condition characterized by severe bone irosion. Osteoclasts, the bone resorbing cells, are overly produced from the synovial inflammatory tissues in RA leading to excessive bone loss. RANKL-signaling pathway has been established to be the major pathway involved in osteclastogenesis. This review highlight the rule of around 40 osteclastogenic factors involved in RANKL-signaling their potential to be targeted for antiresorptiv potential, have been reviewed. Elucidating new potential candidate therapeutic targets in the osteoclastogenesis pathway will open new avenues into the treatment and diagnosis of the arthritic conditions